Document Detail


Interactions between SIRT1 and AP-1 reveal a mechanistic insight into the growth promoting properties of alumina (Al2O3) nanoparticles in mouse skin epithelial cells.
MedLine Citation:
PMID:  18676681     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The physicochemical properties of nanomaterials differ from those of the bulk material of the same composition. However, little is known about the underlying effects of these particles in carcinogenesis. The purpose of this study was to determine the mechanisms involved in the carcinogenic properties of nanoparticles using aluminum oxide (Al(2)O(3)/alumina) nanoparticles as the prototype. Well-established mouse epithelial JB6 cells, sensitive to neoplastic transformation, were used as the experimental model. We demonstrate that alumina was internalized and maintained its physicochemical composition inside the cells. Alumina increased cell proliferation (53%), proliferating cell nuclear antigen (PCNA) levels, cell viability and growth in soft agar. The level of manganese superoxide dismutase, a key mitochondrial antioxidant enzyme, was elevated, suggesting a redox signaling event. In addition, the levels of reactive oxygen species and the activities of the redox sensitive transcription factor activator protein-1 (AP-1) and a longevity-related protein, sirtuin 1 (SIRT1), were increased. SIRT1 knockdown reduces DNA synthesis, cell viability, PCNA levels, AP-1 transcriptional activity and protein levels of its targets, JunD, c-Jun and BcL-xl, more than controls do. Immunoprecipitation studies revealed that SIRT1 interacts with the AP-1 components c-Jun and JunD but not with c-Fos. The results identify SIRT1 as an AP-1 modulator and suggest a novel mechanism by which alumina nanoparticles may function as a potential carcinogen.
Authors:
Swatee Dey; Vasudevan Bakthavatchalu; Michael T Tseng; Peng Wu; Rebecca L Florence; Eric A Grulke; Robert A Yokel; Sanjit Kumar Dhar; Hsin-Sheng Yang; Yumin Chen; Daret K St Clair
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2008-08-01
Journal Detail:
Title:  Carcinogenesis     Volume:  29     ISSN:  1460-2180     ISO Abbreviation:  Carcinogenesis     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-10-02     Completed Date:  2008-10-14     Revised Date:  2011-05-02    
Medline Journal Info:
Nlm Unique ID:  8008055     Medline TA:  Carcinogenesis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1920-9     Citation Subset:  IM    
Affiliation:
Graduate Center for Toxicology, University of Kentucky, 1095 VA Drive, Health Sciences Research Building 454, Lexington, KY 40536-0298, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aluminum Oxide / toxicity*
Animals
Apoptosis / drug effects
Carcinogens / toxicity*
Cell Proliferation / drug effects
Cell Transformation, Neoplastic
Epithelial Cells / drug effects
Mice
Nanoparticles / chemistry,  toxicity*
Proliferating Cell Nuclear Antigen / analysis
Reactive Oxygen Species / metabolism
Sirtuin 1
Sirtuins / physiology*
Skin / drug effects*,  metabolism,  pathology
Superoxide Dismutase / analysis
Transcription Factor AP-1 / physiology*
bcl-X Protein / genetics
Grant Support
ID/Acronym/Agency:
CA 49797/CA/NCI NIH HHS; CA 73599/CA/NCI NIH HHS; R01 CA049797-17/CA/NCI NIH HHS; R01 CA073599-09A1/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Bcl2l1 protein, mouse; 0/Carcinogens; 0/Proliferating Cell Nuclear Antigen; 0/Reactive Oxygen Species; 0/Transcription Factor AP-1; 0/bcl-X Protein; 1344-28-1/Aluminum Oxide; EC 1.15.1.1/Superoxide Dismutase; EC 3.5.1.-/Sirt1 protein, mouse; EC 3.5.1.-/Sirtuin 1; EC 3.5.1.-/Sirtuins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importan...
Next Document:  Interaction between statins and clopidogrel: is there anything clinically relevant?